Abogen Biosciences Wins Prestigious Pieter Cullis Award at the 4th LNP Formulation & Process Development Summit in Boston

Apr 18, 2025 00:02 CST Updated 00:02

Abogen

Nucleic Acid Drug Developer

At the recently concluded event in Boston, USA"4th LNP Formulation & Process Development Summit"Above, Abogen was invited to showcase several breakthrough self-developed achievements represented by the T-cell targeted mRNA-LNP delivery platform. Meanwhile, it was honored with the award of this summit for its world-leading, highly innovative and promising delivery platform.Pieter Cullis Award。This award is a prestigious honor named after Pieter Cullis, the founder of LNP.Abogen is also the only Chinese company to win an award at this summit.

The 4th LNPFormulation and Process Development Summit

Abogen Biosciences Award Ceremony / NEWS TODAY

As the only global event solely dedicated to overcoming the technological bottlenecks of LNP (Lipid Nanoparticle), the annual LNP Formulation and Process Development Summit consistently captures worldwide attention. It not only gathers cutting-edge technological achievements from leading biopharmaceutical companies such as Moderna, Sanofi, AstraZeneca, Takeda, Pfizer, and CureVac, but also continuously drives the transition of LNP technology from fundamental research to clinical application, aiming to shape the future landscape of nucleic acid drug delivery technology.

This year's summit has established four awards aimed at recognizing outstanding achievements in the LNP field, such as significant scientific breakthroughs, lasting contributions to the field, and emerging forces driving industry development. Among them, Abogen Biosciences stands out with itsInternationally leading self-developed projects represented by the T cell-targeting mRNA-LNP delivery platformRecipient of the Pieter Cullis Award,The remaining three awards were won by Sanofi, Moderna, and Croda Research, respectively.

Award Introduction/INTRODUCTION

Pieter Cullis AwardThe award recognizes outstanding scientific achievements in the field of LNP delivery technology.This award, established by the annual LNP Formulation and Process Development Summit, is one of the most prestigious awards of the conference, primarily granted to the presentation demonstrating the highest research quality, strongest innovation, and inThe most outstanding project in enhancing drug delivery potential.

This honor not only represents the attendees' recognition and high praise for Abogen's nucleic acid delivery platform technology, proving its leading strength and innovative spirit in LNP research, but also highlights the global competitiveness of Chinese companies in the field of nucleic acid delivery technology.

Introduction to LNP

LNP is currently recognized as the most advanced non-viral nucleic acid delivery carrier platform. Its efficacy has been fully validated in the clinical application of COVID-19 mRNA vaccines and has been widely used in the delivery of various mRNA drugs, covering fields such as infectious disease vaccines, cancer treatment, and protein replacement therapy.

LNP is a complex system, and its development and characterization process has always been challenging, with empirical skills being particularly crucial in this field. Looking ahead, delivery technologies represented by LNPs will continue to innovate and make breakthroughs in improving delivery efficiency and safety, optimizing production processes, and achieving precise non-liver targeted therapies, opening up broader therapeutic prospects for expanding the application areas of nucleic acid drugs.

AbogenT Cell-Targeting mRNA-LNP Delivery Platform

Abogen's research and development team has successfully developed a highly targeted candidate drug that can circulate in the blood for a long time, does not enter the liver, and can efficiently transfect T cells in vivo after intravenous injection. To address the challenge of balancing systemic circulation time and T-cell transfection efficiency faced by mRNA-LNP formulations in T-cell engineering applications in vivo, this study developed a novel T-cell-targeting mRNA-LNP (tLNP) platform through systematic formulation optimization.

Key Technological Breakthrough

Long-acting circulation characteristics:By optimizing the LNP lipid formulation to avoid liver uptake and prolong systemic circulation time;

Targeted Delivery Mechanism:Achieving CD8+ T cell-specific transfection through surface-conjugated antibodies;

Expression Efficiency Improvement:Screening based on Abogen's proprietary AI-designed ionizable cationic lipid compound library, combined with LNP formulation optimization and the application of circular RNA, significantly improved the transfection efficiency of tLNP in T cells and achieved effective B cell depletion in transgenic mouse models.

In the future, Abogen will continue to deepen its expertise in the field of nucleic acid delivery technology, accelerate the transformation of innovative achievements, promote the innovative application of LNP technology across various therapeutic areas, and contribute Chinese wisdom to the cause of human health.

About the Conference

This summit focuses on the cutting-edge breakthroughs and diverse applications of LNP technology. Three thematic modules (Analytical Development and Characterization, Formulation and Delivery, Process Development and Manufacturing) comprehensively cover the entire LNP development chain, deeply exploring end-to-end strategies from target discovery to industrialization. It is committed to developing efficient, safe, and stable LNP carriers, promoting the targeted delivery revolution in fields such as mRNA drugs and cell therapies.

This summit is themed with“Successfully Fast-Track Your LNPs from Concept to Market”Themed as such, the event attracted giants from multinational pharmaceutical companies like Pfizer, Sanofi, AstraZeneca, and Takeda, as well as pioneers in mRNA technology including Moderna and CureVac. Gathering over 240 authoritative experts in the LNP field globally, more than 50 top experts shared their latest research findings. With an open and sharing attitude, they delved into core topics such as novel ionizable lipid design, breakthroughs in extrahepatic delivery, improvements in thermal stability, and scalable production processes. Serving as a one-stop platform encompassing academic exchange, collaboration matchmaking, and in-depth discussions, this conference accelerates the clinical translation process of LNP technology.